Transdermal testosterone therapy: a potential treatment for selective serotonin reuptake inhibitor (SSRI)-associated sexual dysfunction in women.
Transdermal testosterone therapy: A potential treatment for selective serotonin reuptake inhibitor (SSRI) - associated sexual dysfunction in women being treated for depression
Monash University
96 participants
Mar 25, 2011
Interventional
Conditions
Summary
The Primary Aim of this study is to assess the efficacy of transdermal testosterone therapy on sexual function over 3 months in women at midlife being treated for depression with a selective serotonin re-uptake inhibitor (SSRI) who are experiencing at least one of: loss of sexual desire, sexual arousal disorder or delayed orgasm/anorgasmia for which they desire treatment Study hypothesis Transdermal testosterone, compared with placebo, will result in a clinically meaningful improvement in the total score of the Sabbatsberg Sexual Self Rating Scale indicating improvement in sexual dysfunction secondary to the use of SSRI/SNRI medication .
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Administration of 300 micrograms/day transdermal testosterone via skin patch applied by the patient twice weekly. Patients will be required to wear the patch for 84 hours each time before removal. Patients will undergo the intervention treatment for 3 months.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12610001079033